Your browser doesn't support javascript.
loading
The relationship between obesity and patient-reported outcome measures in people with polymyalgia rheumatica.
Scott, Ian C; Bajpai, Ram; Hider, Samantha L; Helliwell, Toby; Mallen, Christian D; Muller, Sara.
Afiliación
  • Scott IC; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
  • Bajpai R; Haywood Academic Rheumatology Centre, Haywood Hospital, Midlands Partnership University NHS Foundation Trust, Staffordshire, UK.
  • Hider SL; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
  • Helliwell T; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
  • Mallen CD; Haywood Academic Rheumatology Centre, Haywood Hospital, Midlands Partnership University NHS Foundation Trust, Staffordshire, UK.
  • Muller S; Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
Rheumatol Adv Pract ; 8(3): rkae081, 2024.
Article en En | MEDLINE | ID: mdl-39006539
ABSTRACT

Objective:

To examine the association between obesity and patient-reported outcome measures (PROMs) in a primary care-based cohort of people with PMR.

Methods:

The PMR Cohort Study recruited people with incident PMR from 382 general practices. Self-completed questionnaires (0, 12, 24 months) captured a range of PROMs for pain, stiffness, anxiety, depression, fatigue, function and quality of life, alongside data on BMI. People were categorized as underweight/normal weight (BMI < 25kg/m2), overweight (25-29.99 kg/m2) or obese (≥30 kg/m2). Piecewise, multilevel, linear mixed-effects regression models examined relationships between BMI categories and PROMs over time, adjusting for confounding variables. Chi-squared tests examined the relationship between obesity and glucocorticoid persistence.

Results:

644 people with PMR were included. At baseline, 33.9% were normal/underweight, 40.6% overweight and 25.5% obese. Compared with normal/underweight people, those with obesity had significantly worse scores for the following pain and stiffness at 12 months; fatigue at 12 and 24 months; depression at baseline; physical function at all time points; and quality of life at baseline and 12 months. They also had significantly smaller improvements in stiffness (1.13 units on an 11-point numeric rating scale; P = 0.001) and physical function (0.14 units measured using the modified Health Assessment Questionnaire; P = 0.025) between 0 and 12 months. BMI categories did not relate to persistent glucocorticoid use at 12 months (P = 0.110) or 24 months (P = 0.166).

Conclusion:

Obesity associates with poorer outcomes for a range of PROMs in people with PMR. Consideration should be given to providing weight management support to people with PMR and obesity.
Palabras clave